Search Results - "van Moorselaar, R J A"

A protocol for urine collection and storage prior to DNA methylation analysis by Bosschieter, J, Bach, S, Bijnsdorp, I V, Segerink, L I, Rurup, W F, van Splunter, A P, Bahce, I, Novianti, P W, Kazemier, G, van Moorselaar, R J A, Steenbergen, R D M, Nieuwenhuijzen, J A

“…Urine poses an attractive non-invasive means for obtaining liquid biopsies for oncological diagnostics. Especially molecular analysis on urinary DNA is a rapid…”
Get full text

Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy (ADOPT): study protocol for a randomised phase III trial by Janssen, J, Staal, F H E, Brouwer, C L, Langendijk, J A, de Jong, I J, van Moorselaar, R J A, Schuit, E, Verzijlbergen, J F, Smeenk, R J, Aluwini, S

“…More than 60% of oligo-recurrent prostate cancer (PCa) patients treated with metastasis-directed radiotherapy (MDRT) develop biochemical recurrence within…”
Get full text

The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population by Westgeest, H. M., Kuppen, M. C. P., van den Eertwegh, A. J. M., de Wit, R., Bergman, A. M., van Moorselaar, R. J. A., Coenen, J. L. L. M., van den Bergh, A. C. M., Somford, D. M., Mehra, N., van Oort, I. M., Aben, K. K. H., Gerritsen, W. R., Uyl-de Groot, C. A.

“…Background In 2004 docetaxel was the first life-prolonging drug (LPD) registered for metastatic castration-resistant prostate cancer (mCRPC) patients. Between…”
Get full text

Early lesion detection with 18F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer by Wondergem, M., Jansen, B. H. E., van der Zant, F. M., van der Sluis, T. M., Knol, R. J. J., van Kalmthout, L. W. M., Hoekstra, O. S., van Moorselaar, R. J. A., Oprea-Lager, D. E., Vis, A. N.

“…Purpose Prostate-specific membrane antigen (PSMA) PET/CT is increasingly used in patients with biochemically recurrent prostate cancer (BCR), mostly using…”
Get full text

Renal cancer and pneumothorax risk in Birt–Hogg–Dubé syndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families by Houweling, A C, Gijezen, L M, Jonker, M A, van Doorn, M B A, Oldenburg, R A, van Spaendonck-Zwarts, K Y, Leter, E M, van Os, T A, van Grieken, N C T, Jaspars, E H, de Jong, M M, Bongers, E M H F, Johannesma, P C, Postmus, P E, van Moorselaar, R J A, van Waesberghe, J-Htm, Starink, T M, van Steensel, M A M, Gille, J J P, Menko, F H

“…Background: Birt–Hogg–Dubé (BHD) syndrome is an autosomal dominant condition caused by germline FLCN mutations, and characterised by fibrofolliculomas,…”
Get full text

Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial by Jansen, B. H. E., Bodar, Y. J. L., Zwezerijnen, G. J. C., Meijer, D., van der Voorn, J. P., Nieuwenhuijzen, J. A., Wondergem, M., Roeleveld, T. A., Boellaard, R., Hoekstra, O. S., van Moorselaar, R. J. A., Oprea-Lager, D. E., Vis, A. N.

“…Purpose The detection of lymph-node metastases (N1) with conventional imaging such as magnetic resonance imaging (MRI) and computed tomography (CT) is…”
Get full text

New experimental markers for early detection of high-risk prostate cancer : role of cell-cell adhesion and cell migration by MOL, A. J. M, GELDOF, A. A, MEIJER, G. A, VAN DER POEL, H. G, VAN MOORSELAAR, R. J. A

“…Today's treatment and diagnosis of prostate cancer still exhibit major limitations. The search for new and additional prognostic markers is therefore still an…”
Get full text

Letter to the Editor re: Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake by Cysouw, M. C. F., Jansen, B. H. E., Yaqub, M., Voortman, J., Vis, A. N., van Moorselaar, R. J. A., Hoekstra, O. S., Boellaard, R., Oprea-Lager, D. E.

Get full text

Detection of prostate cancer with 18F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial by Bodar, Y. J. L., Jansen, B. H. E., van der Voorn, J. P., Zwezerijnen, G. J. C., Meijer, D., Nieuwenhuijzen, J. A., Boellaard, R., Hendrikse, N. H., Hoekstra, O. S., van Moorselaar, R. J. A., Oprea-Lager, D. E., Vis, A. N.

“…Purpose In primary prostate cancer (PCa) patients, accurate staging and histologic grading are crucial to guide treatment decisions. 18 F-DCFPyL (PSMA)-PET/CT…”
Get full text

Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: a validation study by Ingels, A., Hew, M., Algaba, F., de Boer, O. J., van Moorselaar, R. J. A., Horenblas, S., Zondervan, P., de la Rosette, J. J. M. C. H., Pilar Laguna Pes, M.

“…Purpose Clinical outcomes prognostic markers are awaited in clear-cell renal carcinoma (ccRCC) to improve patient-tailored management and to assess six…”
Get full text

Functional outcomes rather than complications predict poor health-related quality of life at 6 months after robot-assisted radical prostatectomy by Hagens, Marinus J., Veerman, H., de Ligt, K. M., Tillier, C. N., van Leeuwen, P. J., van Moorselaar, R. J. A., van der Poel, H. G.

“…The objective is to evaluate the effect of robot-assisted radical prostatectomy (RARP)-related postoperative complications on the 6-month postoperative…”
Get full text

Correction to: Letter to the Editor re: Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake by Cysouw, M. C. F., Jansen, B. H. E., Yaqub, M., Voortman, J., Vis, A. N., van Moorselaar, R. J. A., Hoekstra, O. S., Boellaard, R., Oprea-Lager, D. E.

“…The article was updated to correct the following errors due to an error in production:…”
Get full text

Variation in the management of cT1 renal cancer by surgical hospital volume: A nationwide study by Yildirim, H., Schuurman, M. S., Widdershoven, C. V., Lagerveld, B. W., Brink, L., Ruiter, A. E. C., Beerlage, H. P., Moorselaar, R. J. A., Graafland, N. M., Bex, A., Aben, K. K. H., Zondervan, P. J.

“…Objectives To analyse variation in clinical management of cT1 renal cell carcinoma (RCC) in the Netherlands related to surgical hospital volume (HV). Materials…”
Get full text

A predictive role for noncancerous prostate cells: low connexin-26 expression in radical prostatectomy tissues predicts metastasis by Bijnsdorp, I V, Rozendaal, L, van Moorselaar, R J A, Geldof, A A

“…Background: It is important to identify markers that predict whether prostate cancer will metastasise. The adjacent noncancerous cells (influenced by the…”
Get full text

Risk of spontaneous pneumothorax due to air travel and diving in patients with Birt–Hogg–Dubé syndrome by Johannesma, P. C., van de Beek, I., van der Wel, J. W. T., Paul, M. A., Houweling, A. C., Jonker, M. A., van Waesberghe, J. H. T. M., Reinhard, R., Starink, Th. M., van Moorselaar, R. J. A., Menko, F. H., Postmus, P. E.

“…Background and objectives Birt–Hogg–Dubé syndrome is an autosomal dominant disorder characterized by skin fibrofolliculomas, lung cysts, spontaneous…”
Get full text

Customized Tool for the Validation of Optical Coherence Tomography in Differentiation of Prostate Cancer by Muller, B. G., Swaan, A., de Bruin, D. M., van den Bos, W., Schreurs, A. W., Faber, D. J., Zwartkruis, E. C. H., Rozendaal, L., Vis, A. N., Nieuwenhuijzen, J. A., van Moorselaar, R. J. A., van Leeuwen, T. G., de la Rosette, J. J. M. C. H.

“…Objective: To design and demonstrate a customized tool to generate histologic sections of the prostate that directly correlate with needle-based optical…”
Get full text

Needle-based optical coherence tomography for the detection of prostate cancer: a visual and quantitative analysis in 20 patients by Muller, Berrend G, van Kollenburg, Rob A. A, Swaan, Abel, Zwartkruis, Evita C. H, Brandt, Martin J, Wilk, Leah S, Almasian, Mitra, Schreurs, A. Wim, Faber, Dirk J, Rozendaal, L. Rence, Vis, Andre N, Nieuwenhuijzen, Jakko A, van Moorselaar, Jeroen R. J. A, de la Rosette, Jean J. M. C. H, de Bruin, Daniel Martijn, van Leeuwen, Ton G

“…Diagnostic accuracy of needle-based optical coherence tomography (OCT) for prostate cancer detection by visual and quantitative analysis is defined. 106…”
Get full text

Bladder Cancer detection by urinary methylation markers GHSR/MAL: a validation study by Beijert, I. J., van den Burgt, Y., Hentschel, A. E., Bosschieter, J., Kauer, P. C., Lissenberg-Witte, B. I., van Moorselaar, R. J.A., Nieuwenhuijzen, J. A., Steenbergen, R. D.M.

“…Purpose Although cystoscopy is a reliable tool for detecting bladder cancer, it poses a high burden on patients and entails high costs. This highlights the…”
Get full text

A prospective, multicenter head-to-head comparative study in patients with primary high-risk prostate cancer investigating the bone lesion detection of conventional imaging and 18F-PSMA-PET/CT by Bodar, Y.J.L., Luining, W.I., Keizer, B., Meijer, D., Vellekoop, A., Schaaf, M., Hendrikse, N.H., Van Moorselaar, R.J.A., Oprea-Lager, D.E., Vis, A.N.

“…•After negative bone scintigraphy, upstaging on prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) occurred…”
Get full text

Metastatic disease after removal of a renal cell carcinoma smaller than 3 cm in a patient with Birt-Hogg-Dubé syndrome, a case report by van Riel, L., Kets, C. M., van Hest, L. P., Menko, F. H., Boerrigter, B. G., Franken, S. M., Wolthuis, R. M.F., Dubbink, H. J., Zondervan, P. J., van Moorselaar, R. J.A., Houweling, A. C., van de Beek, I.

Get full text